Jan 13, 2026 7:01am EST Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Dec 02, 2025 7:00am EST Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Nov 28, 2025 9:20am EST Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Nov 25, 2025 7:00am EST Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
Nov 24, 2025 7:00am EST Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
Nov 21, 2025 12:35pm EST Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Nov 20, 2025 4:01pm EST Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Nov 04, 2025 7:03am EST Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Sep 16, 2025 7:03am EDT Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Sep 08, 2025 7:01am EDT Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
